VP
ARTV

venBio Partners’s Artiva Biotherapeutics ARTV Stock Holding History

venBio Partners’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.42M Sell
531,337
-117,170
-18% -$580K 1.22% 6
2025
Q4 		$2.78M Sell
648,507
-500,468
-44% -$1.89M 1.29% 6
2025
Q3 		$3.3M Hold
1,148,975
– – 1.87% 6
2025
Q2 		$1.73M Sell
1,148,975
-50,000
-4% -$105K 1.51% 6
2025
Q1 		$3.6M Sell
1,198,975
-320,996
-21% -$1.73M 2.91% 7
2024
Q4 		$15.3M Hold
1,519,971
– – 8.98% 5
2024
Q3 		$23.5M Buy
+1,519,971
New +$17.6M 12.08% 4

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

venBio Partners's ARTV Position: Q1 2026 in Review

venBio Partners reduced its Artiva Biotherapeutics (ARTV) stake by 18% in Q1 2026, selling an estimated $580K and leaving 531,337 shares worth $3.42M. The position accounts for 1.22% of the portfolio, ranked #6.

venBio Partners first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $23.5M in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • venBio Partners held 531,337 shares of Artiva Biotherapeutics worth $3.42M as of Q1 2026.
  • venBio Partners sold 117,170 Artiva Biotherapeutics shares in Q1 2026, an estimated $580K.
  • Artiva Biotherapeutics made up 1.22% of venBio Partners's portfolio in Q1 2026, its #6 holding.
  • venBio Partners first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • venBio Partners's Artiva Biotherapeutics position peaked at $23.5M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on venBio Partners's 13F filing for Q1 2026, filed 15 May 2026.